**Seno Medical Secures Vizient Contract to Advance Breast Cancer Diagnosis Technology**
In a significant step forward for breast cancer diagnostics, Seno Medical, a leading innovator in medical imaging technology, has announced its partnership with Vizient, the largest member-driven healthcare performance improvement company in the United States. This strategic contract is poised to accelerate the adoption of Seno Medical’s groundbreaking Imagio® Breast Imaging System, a technology that combines ultrasound and opto-acoustic imaging to improve the accuracy and efficiency of breast cancer diagnosis.
### A New Era in Breast Cancer Diagnostics
Breast cancer remains one of the most prevalent cancers worldwide, with early and accurate diagnosis being critical to improving patient outcomes. Traditional diagnostic methods, such as mammography and ultrasound, often require follow-up biopsies to confirm malignancy, leading to increased patient anxiety, higher healthcare costs, and potential delays in treatment.
Seno Medical’s Imagio® Breast Imaging System offers a revolutionary approach to breast cancer diagnostics. By integrating opto-acoustic imaging with traditional ultrasound, the system provides real-time, non-invasive visualization of blood vessel patterns and oxygenation levels in breast tissue. These features are critical indicators of malignancy, enabling physicians to distinguish between benign and malignant lesions with greater confidence. The technology reduces the need for unnecessary biopsies, streamlines the diagnostic process, and enhances the overall patient experience.
### The Vizient Partnership: A Catalyst for Change
Vizient serves more than 60% of the nation’s acute care providers and represents over $130 billion in annual purchasing volume. By securing a contract with Vizient, Seno Medical gains access to a vast network of healthcare providers, paving the way for widespread adoption of the Imagio® Breast Imaging System. This partnership underscores the growing recognition of Seno Medical’s technology as a game-changer in breast cancer diagnostics.
The contract will allow Vizient members to access the Imagio® system at negotiated pricing, making it more affordable and accessible for hospitals and clinics across the country. This is particularly significant as healthcare providers continue to seek innovative solutions to improve patient care while managing costs.
### Benefits for Patients and Providers
The collaboration between Seno Medical and Vizient is expected to deliver several key benefits:
1. **Improved Diagnostic Accuracy**: The Imagio® system’s ability to provide detailed insights into tissue composition and vascular patterns enhances diagnostic precision, reducing false positives and negatives.
2. **Fewer Unnecessary Biopsies**: By offering a more definitive assessment of breast lesions, the technology minimizes the need for invasive procedures, sparing patients from physical and emotional stress.
3. **Cost Savings**: With fewer biopsies and streamlined diagnostic workflows, healthcare providers can achieve significant cost savings, which can be reinvested into other areas of patient care.
4. **Enhanced Patient Experience**: The non-invasive nature of the Imagio® system, combined with its ability to deliver immediate results, improves the overall patient journey, fostering trust and satisfaction.
### A Commitment to Innovation
S